

Ref No. LASA/SE/17-18/013

Wednesday November 22, 2017

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
---	---

Dear Sir/Madam,

Sub: Intimation of pilot production trial Run in Unit IV of the company

Pursuant to the provisions of Schedule III, Part B of SEBI (Listing Obligation and disclosure requirements) Regulations, 2015 read with regulation 30(4), we would like to inform you that company is to start its pilot production trial runs in UNIT IV from 25.11.2017.

Products & capacity per annum will include Albendazole Intermediate 400 MT, Fenbendazole Intermediate 200MT, 2 4 DCP 600MT, Closantel Intermediate 100MT and additionally few components of backward integration for its recent new launches.

Regular production will be subject to successful trial.

This is for your information

Kindly take the above on your record and acknowledge.

Thanking you

For LASA SUPERGENERICS LIMITED

OMKAR P. HELRLEKAR
CHAIRMAN AND MANAGING DIRECTOR
DIN : 01587154

